Eli Lilly's Mirikizumab Improves Fatigue in Crohn's Disease Patients
- As a part of a pre-specified analysis of the Phase 2 SERENITY study, new data showed that Eli Lilly And Co's (NYSE: LLY) mirikizumab improved fatigue in patients with moderately to severely active Crohn's disease (CD) at 12 weeks. Improvements were sustained up to one year.
- The results were presented at Digestive Disease Week.
- "New data show that fatigue is more than a symptom of ulcerative colitis and Crohn's disease. It can also be an important predictor for the severity of a person's disease", said the lead author of these analyses.
- In SERENITY, patients treated with mirikizumab saw improved fatigue during the induction period of 12 weeks from baseline compared to placebo.
- Mirikizumab is a humanized IgG4 monoclonal antibody that binds to the p19 subunit of interleukin 23.
- Last month, the company scrapped its plans to seek approval for mirikizumab in psoriasis.
- Price Action: LLY shares closed at $199.88 on Friday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: Briefs Crohn's DiseaseBiotech News Health Care FDA General
